# A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

> **NCT02148861** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 49 (actual)

## Conditions studied

- Diabetes
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin icodec
- **DRUG:** insulin degludec
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02148861
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-26
- **Primary completion:** 2015-06-01
- **Final completion:** 2015-06-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02148861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02148861, "A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02148861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*